Targeted therapy for BRAF-mutated colorectal cancer has evolved from conventional anti-VEGF/anti-EGFR based regimens to BRAF targeted therapy; however, none achieved substantial clinical benefits until the BEACON trial established the efficacy of dual EGFR/BRAF inhibition. This evidence concerns the gene EGFR and colorectal cancer.